GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » RaySearch Laboratories AB (OSTO:RAY B) » Definitions » Cash And Cash Equivalents

RaySearch Laboratories AB (OSTO:RAY B) Cash And Cash Equivalents : kr435 Mil (As of Jun. 2024)


View and export this data going back to 1991. Start your Free Trial

What is RaySearch Laboratories AB Cash And Cash Equivalents?

RaySearch Laboratories AB's quarterly cash and cash equivalents increased from Dec. 2023 (kr343.68 Mil) to Mar. 2024 (kr440.13 Mil) but then stayed the same from Mar. 2024 (kr440.13 Mil) to Jun. 2024 (kr435.20 Mil).

RaySearch Laboratories AB's annual cash and cash equivalents increased from Dec. 2021 (kr102.54 Mil) to Dec. 2022 (kr160.27 Mil) and increased from Dec. 2022 (kr160.27 Mil) to Dec. 2023 (kr343.68 Mil).


RaySearch Laboratories AB Cash And Cash Equivalents Historical Data

The historical data trend for RaySearch Laboratories AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RaySearch Laboratories AB Cash And Cash Equivalents Chart

RaySearch Laboratories AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 113.86 168.75 102.54 160.27 343.68

RaySearch Laboratories AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 246.23 306.63 343.68 440.13 435.20

RaySearch Laboratories AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


RaySearch Laboratories AB  (OSTO:RAY B) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


RaySearch Laboratories AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of RaySearch Laboratories AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


RaySearch Laboratories AB Business Description

Traded in Other Exchanges
Address
Sveavagen 44, P.O. Box 3297, Stockholm, SWE, 103 65
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia, Europe and the rest of the world. The company generates majority of its sales from the North America.

RaySearch Laboratories AB Headlines

No Headlines